The approval of Wyost and Jubbonti by the European Commission is a significant milestone for Sandoz, as it allows the company to market the first biosimilars of denosumab in Europe. This approval is likely to enhance Sandoz's market position and revenue potential in the biosimilars segment, particularly in the treatment of cancer-related bone disease and osteoporosis.